Atnaujinkite slapukų nuostatas

El. knyga: Metallo-Drugs: Development and Action of Anticancer Agents

Contributions by , Contributions by , Contributions by , Edited by , Edited by , Edited by , Contributions by , Edited by , Contributions by , Contributions by
  • Formatas: 588 pages
  • Serija: Metal Ions in Life Sciences
  • Išleidimo metai: 05-Feb-2018
  • Leidėjas: De Gruyter
  • Kalba: eng
  • ISBN-13: 9783110469905
Kitos knygos pagal šią temą:
Metallo-Drugs: Development and Action of Anticancer AgentsDidesnis paveikslėlis
  • Formatas: 588 pages
  • Serija: Metal Ions in Life Sciences
  • Išleidimo metai: 05-Feb-2018
  • Leidėjas: De Gruyter
  • Kalba: eng
  • ISBN-13: 9783110469905
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Volume 18, entitled Metallo-Drugs: Development and Action of Anticancer Agents of the series Metal Ions in Life Sciences centers on biological, medicinal inorganic chemistry. The serendipitous discovery of the antitumor activity of cis-diamminodichloroplatinum(II) (cisplatin) by Barnett Rosenberg in the 1960s is a landmark in metallodrug-based chemotherapy. The success of cisplatin in the clinic, followed by oxaliplatin and carboplatin, along with their drawbacks relating mainly to resistance development and severe toxicity, initiated research on polynuclear platinum complexes and on Pt(IV) complexes as prodrugs. Furthermore, the indicated shortcomings led to the exploration of other transition and main group metal ions, among them Ru(II/III), Au(I/III), Ti(IV), V(IV/V), and Ga(III) including also the essential metal ions Fe(II/III), Cu(I/II), and Zn(II). Ionic as well as covalent and non-covalent interactions between structurally very different complexes and biomolecules like nucleic acids, proteins, and carbohydrates are studied and discussed with regard to their possible anticancer actions. Hence, MILS-18 summarizes the research at the forefront of medicinal inorganic chemistry, including studies on the next-generation, tailor-made anticancer drugs. All this and more is treated in an authoritative and timely manner in the 17 stimulating chapters of this book, written by 39 internationally recognized experts from 10 nations (from the US via Europe to China and Australia). The impact of this vibrant research area is manifested by more than 2700 references, nearly 150 illustrations (more than half in color) and several comprehensive tables. Metallo-Drugs: Development and Action of Anticancer Agents is an essential resource for scientists working in the wide range from enzymology, material sciences, analytical, organic, and inorganic biochemistry all the way through to medicine including the clinic ... not forgetting that it also provides excellent information for teaching.
About The Editors v
Historical Development And Perspectives Of The Series vii
Preface To Volume 18 ix
Contributors To Volume 18 xix
Titles Of Volumes 1 44 In The Metal Ions In Biological Systems Series xxiii
Contents Of Volumes Em The Metal Ions In Life Sciences Series xxv
1 Cisplatin And Oxaliplatin: Our Current Understanding Of Their Actions
1
Imogen A. Riddell
Stephen J. Lippard
1 Introduction
2(4)
2 Cellular Uptake and Efflux/Membrane Transport
6(7)
3 Covalent Adducts Generated with Platinum Agents
13(5)
4 Cellular Processing of Platinum DNA Adducts
18(7)
5 Signal Transduction Pathways Activated by Platinum DNA Damage
25(5)
6 Undesired Consequences of Platinum-Based Chemotherapy
30(3)
7 Concluding Remarks and Future Directions
33(1)
Acknowledgments
34(1)
Abbreviations and Definitions
34(1)
References
35(8)
2 Polynuclear Platinum Complexes. Structural Diversity And Dna Binding
43(26)
Viktor Brabec
Jana Kasparkova
Vijay Menon
Nicholas P. Farrell
Abstract
44(1)
1 Introduction
44(2)
2 Dinuclear Bifunctional Platinum(II) Complexes with Alkanediamine Linkers
46(3)
3 Polyamine-Linked Bifunctional Dinuclear Platinum(II) Complexes
49(4)
4 DNA-Protein Crosslinking
53(1)
5 Dinuclear Platinum(II) Complexes Stabilizing G-DNA Quadruplexes
53(2)
6 Structural Variation in Dinuclear Platinum(II) Complexes
55(1)
7 Trinuclear Platinum(II) Complexes
56(6)
8 Conclusions and Outlook
62(1)
Acknowledgments
63(1)
Abbreviations and Definitions
63(1)
References
64(5)
3 Platinum(Iv) Prodrugs
69(40)
V. Venkatesh
Peter J. Sadler
Abstract
70(1)
1 Introduction
70(7)
2 Interactions with Biomolecules
77(3)
3 Design Features for Anticancer Complexes
80(8)
4 Photoactivatable Complexes
88(4)
5 Nano Materials for Drug Delivery
92(9)
6 Concluding Remarks
101(1)
Acknowledgments
102(1)
Abbreviations
102(1)
References
103(6)
4 Metalloglycomics
109(32)
Nicholas P. Farrell
Anil K. Gorle
Erica J. Peterson
Susan J. Berners-Price
Abstract
110(1)
1 Introduction. Metalloglycomics, Heparin, and Heparan Sulfate
110(2)
2 Structure and Conformation of Heparin and Heparan Sulfate
112(6)
3 Interaction of Metal Ions with Glycosaminoglycans
118(3)
4 Interaction of Coordination Compounds with Glycosaminoglycans
121(7)
5 Consequences of High-Affinity Heparan Sulfate Binding
128(6)
6 Use of Metal Complexes in Heparin Analysis
134(1)
7 Conclusions and Outlook
135(1)
Acknowledgments
135(1)
Abbreviations and Definitions
135(1)
References
136(5)
5 The Deceptively Similar Ruthenium(III) Drug Candidates Kp1019 And Nami-A Have Different Actions. What Did We Learn In The Past 30 Years?
141(30)
Enzo Alessio
Luigi Messori
Abstract
142(1)
1 Introduction
142(3)
2 Comparison of NAMI-A and KP1019
145(19)
3 Conclusions and Outlook
164(1)
Acknowledgments
165(1)
Abbreviations and Definitions
165(1)
References
166(5)
6 Multinuclear Organometallic Ruthenium-Arene Complexes For Cancer Therapy
171(28)
Maria V. Babak
Wee Han Ang
Abstract
172(1)
1 Introduction
172(2)
2 Homoleptic Dinuclear Complexes
174(4)
3 Homoleptic Trinuclear and Tetranuclear Complexes
178(3)
4 Polynuclear Ruthenium-Arene Cages
181(5)
5 Heteronuclear Ruthenium-Arene Complexes
186(6)
6 Conclusions
192(1)
Acknowledgments
193(1)
Abbreviations
193(1)
References
194(5)
7 Medicinal Chemistry Of Gold Anticancer Metallodrugs
199(20)
Angela Casini
Raymond Wai-Yin Sun
Ingo Ott
Abstract
200(1)
1 Introduction
200(1)
2 Current Status of Registered Gold Drugs
200(2)
3 Gold(I) Anticancer Drugs
202(3)
4 Gold(III) Anticancer Drugs
205(3)
5 Biological Functions of Gold Complexes
208(5)
6 General Conclusions
213(1)
Acknowlegments
213(1)
Abbreviations and Definitions
214(1)
References
214(5)
8 Coordination Complexes Of Titanium(Iv) For Anticancer Therapy
219(32)
Edit Y. Tshuva
Maya Miller
Abstract
219(1)
1 Introduction
220(1)
2 Cyclopentadienyl-Based Complexes
221(6)
3 Budotitane and Related Diketonato Complexes
227(3)
4 Complexes of Phenolato Ligands
230(7)
5 Conlusions and Outlook
237(3)
Acknowledgments
240(1)
Abbreviations and Definitions
240(1)
References
240(11)
9 Health Benefits Of Vanadium And Its Potential As An Anticancer Agent
251(30)
Debbie C. Crans
Lining Yang
Allison Haase
Xiaogai Yang
Abstract
252(1)
1 Introduction: Vanadium-Containing Compounds Induce Biological Actions
252(2)
2 Applications of Vanadium Compounds in Human Studies
254(4)
3 Biological Chemistry of Vanadium
258(4)
4 The Anticancer Effects of Vanadium Compounds
262(3)
5 Vanadium-Containing Drugs in Context of Other Diseases
265(2)
6 Vanadium-Based Drugs and Additives and Their Formulation
267(5)
7 Conclusions and Outlook
272(1)
Acknowledgments
273(1)
Abbreviations
273(1)
References
274(7)
10 Gallium Complexes As Anticancer Drugs
281(22)
Christopher R. Chitambar
Abstract
282(1)
1 History
282(1)
2 Chemistry
283(1)
3 Gallium-Based Agents in Clinical Use. Pharmacology and Efficacy
283(5)
4 Cellular Handling of Gallium
288(2)
5 Antineoplastic Mechanism of Clinically Used Gallium Compounds
290(4)
6 Gallium Compounds in Preclinical Development
294(2)
7 Summary and Outlook
296(1)
Acknowledgments
297(1)
Abbreviations
297(1)
References
297(6)
11 Non-Covalent Metallo-Drugs: Using Shape To Target Dna And Rna Junctions And Other Nucleic Acid Structures
303(22)
Lucia Cardo
Michael J. Hannon
Abstract
304(1)
1 Introduction
304(1)
2 Metallo-Cylinders
304(6)
3 Other Supramolecular Designs and Their Targets
310(9)
4 Concluding Remarks and Future Directions
319(1)
Acknowledgments
320(1)
Abbreviations and Definitions
320(1)
References
321(4)
12 Nucleic Acid Quadruplexes And Metallodrugs
325(26)
Ramon Vilar
Abstract
325(1)
1 Introduction
326(1)
2 G-Quadruplexes and Their Biological Roles
327(1)
3 Metal Complexes as G-Quadruplex Binders
328(10)
4 Metal-Based Optical Probes for G-Quadruplexes
338(2)
5 Biological Activity of Metal-Based G-Quadruplex Binders
340(4)
6 Concluding Remarks and Future Directions
344(1)
Acknowledgments
344(1)
Abbreviations
344(1)
References
345(6)
13 Antitumor Metallodrugs That Target Proteins
351(36)
Matthew P. Sullivan
Hannah U. Holtkamp
Christian G. Hartinger
Abstract
352(1)
1 Introduction
352(2)
2 Anticancer Metallodrugs that Target Carrier Proteins
354(8)
3 Selected Cancer-Related Proteins as Targets
362(11)
4 Non-Conventional Protein Targets for Anticancer Metallodrugs
373(2)
5 Modern Bioanalytical Methods
375(1)
6 Concluding Remarks and Future Directions
376(1)
Acknowledgments
377(1)
Abbreviations
377(2)
References
379(8)
14 Metallointercalators And Metalloinsertors: Structural Requirements For Dna Recognition And Anticancer Activity
387(50)
Ulrich Schatzschneider
Abstract
388(1)
1 Introduction
388(1)
2 The Basics: Nucleic Acid Structure and Enzymatic Processing
389(5)
3 Analytical Methods to Study Metal Complex-DNA Interactions
394(2)
4 Metallointercalators
396(17)
5 Metalloinsertors
413(13)
6 Concluding Remarks and Future Directions
426(1)
Abbreviations and Definitions
427(3)
References
430(7)
15 Iron And Its Role In Cancer Defense: A Double-Edged Sword
437(32)
Frank Thevenod
Abstract
438(1)
1 Introduction
438(1)
2 Short Overview of Systemic and Cellular Iron Homeostasis
439(2)
3 Iron and Cancer Formation: "A Predominant Feature"
441(3)
4 Iron and Cancer Defense: "Long Live the Difference"
444(12)
5 General Conclusions
456(1)
Acknowledgments
456(1)
Abbreviations and Definitions
456(2)
References
458(11)
16 Copper Complexes In Cancer Therapy
469(38)
Delphine Denoyer
Sharnel A. S. Clatworthy
Michael A. Cater
Abstract
470(1)
1 Introduction
470(7)
2 Repurposing Old Copper Complexes for Cancer Treatment
477(12)
3 Emerging Classes of Copper Complexes for Cancer Treatment
489(7)
4 General Conlusions
496(1)
Acknowledgments
497(1)
Abbreviations
497(1)
References
498(9)
17 Targeting Zinc(II) Signalling To Prevent Cancer
507(24)
Silvia Ziliotto
Olivia Ogle
Kathryn M. Taylor
Abstract
507(1)
1 Introduction
508(1)
2 Zinc Handling in Cells
508(5)
3 Zinc in Cancer
513(5)
4 Zinc Signalling in Cancer
518(2)
5 Targeting Zinc Signalling Mechanisms in Cancer
520(3)
6 General Conclusions
523(1)
Acknowledgments
523(1)
Abbreviations and Definitions
524(1)
References
524(7)
Subject Index 531
Helmut and Astrid Sigel, University of Basel, Switzerland; Roland K. O. Sigel and Eva Freisinger, University of Zürich, Switzerland.
Daugiau apie elektronines knygas Daugiau apie elektronines knygas
Pastovi nuoroda: https://www.kriso.lt/db/97831104699056e.html